INTERNATIONAL PhD PROGRAM IN NEUROPHARMACOLOGY
UNIVERSITY OF CATANIA

SUMMER SCHOOL OF NEUROSCIENCE (8)
Ottava scuola estiva di Neuroscienze (8)

UNDER THE AUSPICES
OF THE FEDERATION OF EUROPEAN PHARMACOLOGICAL SOCIETIES
(EPHAR)
THE ITALIAN SOCIETY OF PHARMACOLOGY
(SIF)
AND THE ITALIAN SOCIETY OF NEUROPSYCHOPHARMACOLOGY
(SINPF)

July 10-16, 2010

SCHIZOPHRENIA AND OTHER PSYCHOSES:
WHAT CAN CLINICS LEARN FROM BASIC SCIENCE?

Catania
Parco degli Aragonesi Hotel
Viale Kennedy, 2
Scientific Advisory Board

Filippo Drago (Catania)
(Chairman)

Eugenio Aguglia (Catania)

Pier Luigi Canonico (Novara)

Vincenzo Cuomo (Rome)

Donatella Marazziti (Pisa)

Giancarlo Pepeu (Florence)

Giorgio Racagni (Milan)

Maria Angela Sortino (Catania)

Scientific Secretariat

Filippo Caraci (Catania)
Saturday July 10th, 2010

09.00-09.45  Registration

09.45-10.00  Opening remarks  
Filippo Drago (Catania)

10.00-11.00  Opening lecture  (introduced by Filippo Drago)  
Gene-environment interaction in psychotic disorders  
Alessandro Guidotti (Chicago, USA)

11.00-11.30  Welcome reception

Psychotic disorders: epidemiology and genetics

16.00-17.00  Psychotic disorders: epidemiology and risk factors  
Jim Van Os (The Netherlands)

17.00-18.00  The genetics of bipolar spectrum disorders  
Alessandro Serretti (Italy)

18.00-18.30  Discussion

18.30-19.30  Genetics of schizophrenia: new insights from new approaches  
Peter Burbach (The Netherlands)

19.30-19.40  Questionnaire
Schizophrenia: animal models

10.00-11.00 Overview on animal models of schizophrenia
   Mark Millan (France)

11.00-12.00 Neural basis of psychosis-related behaviour in the infection model of schizophrenia
   Urs Meyer (Switzerland)

12.00-12.30 Discussion

12.30-13.30 Sponsored lecture

Schizophrenia: from diagnosis to treatment

16.00-17.00 Early diagnosis and early intervention in Schizophrenia
   Shon Lewis (United Kingdom)

17.00-18.00 Factors affecting long-term outcome in schizophrenia
   Carlo Altamura (Italy)

18.00-18.30 Discussion

18.30-19.30 Special Lecture:
   Neurodegeneration in Schizophrenia: implications for the treatment
   Rene Kahn (The Netherlands)

19.30-19.40 Questionnaire
Monday July 12th, 2010

Neurobiology of schizophrenia: the role of glutamate

10.00-11.00 Abnormal dopamine-glutamate interactions in the pathogenesis of schizophrenia
James Stone (United Kingdom)

11.00-12.00 Metabotropic glutamate receptors as new therapeutic targets for the treatment of schizophrenia
Ferdinando Nicoletti (Italy)

12.00-12.30 Discussion

12.30-13.30 Sponsored lecture

Cognitive function in schizophrenia: new insights

16.00-17.00 Cognitive dysfunctions as endophenotypes of schizophrenia: neurobiological correlates
Silvana Galderisi (Italy)

17.00-18.00 Cognitive impairment and long-term outcome in schizophrenia
Eugenio Aguglia (Italy)

18.00-18.30 Discussion

18.30-19.30 Special Lecture:
Cognitive effects of antipsychotic drugs
Michael Davidson (Israel)

19.30-19.40 Questionnaire
Tuesday July 13\textsuperscript{rd}, 2010

**Drug discovery in schizophrenia**

10.00-11.00  Searching for new pharmacological targets in schizophrenia  
Andrea De Bartolomeis (Italy)

11.00-12.00  New approaches for antipsychotic drug development  
Luca Pani (Italy)

12.00-12.30  Discussion

12.30-13.30  Sponsored lecture

**Pharmacological treatment of schizophrenia**

16.00-17.00  Second-generation versus first-generation antipsychotic drugs for schizophrenia: which evidence?  
Stephan Leucht (Germany)

17.00-18.00  Neuroimaging and response to treatment with antipsychotics in schizophrenia  
Alessandro Bertolino (Italy)

18.00-18.30  Discussion

18.30-19.30  Special Lecture:  
Pharmacogenetics of antipsychotic response  
Alexandre Meary (France)

19.30-19.40  Questionnaire
Wednesday July 14\textsuperscript{th}, 2010

Safety of antipsychotics: from pre-clinical evidence to regulatory restrictions

10.00-11.00  Cardiovascular risks of antipsychotic treatment  
\textit{Milou-Daniel Drici (France)}

11.00-12.00  Antipsychotic drugs and the risk of cerebrovascular events: which evidence?  
\textit{Emilio Sacchetti (Italy)}

12.00-12.30  Discussion

12.30-13.30  Sponsored lecture

Bipolar disorder: from diagnosis to long-term treatment

16.00-17.00  Bipolar depression: diagnostic guidelines and treatment options  
\textit{Guy Goodwin (United Kingdom)}

17.00-18.00  Mixed states: clinical subtyping and implications for the treatment  
\textit{Eduard Vieta (Spain)}

18.00-18.30  Discussion

18.30-19.30  Special lecture:  
Treating mania and managing long-term treatment of bipolar disorder  
\textit{Siegfried Kasper (Austria)}

19.30-19.40  Questionnaire
Thursday July 15th, 2010

Bipolar disorder: neurobiology and neuropharmalogy

10.00-11.00 Neurobiological trait abnormalities in bipolar disorder
   Camilla Langan (Ireland)

11.00-12.00 Molecular mechanisms underlying mood stabilizers efficacy: lessons from lithium
   Robert Belmaker (Israel)

12.00-12.30 Discussion

12.30-13.30 Sponsored lecture

Psychosis in neurological disorders: from diagnosis to treatment

16.00-17.00 Psychotic disorders in epilepsy: etiology, clinical features, and therapeutic implications
   Riccardo Rorta (Italy)

17.00-18.00 Psychosis in Parkinson’s disease: from diagnosis to treatment
   Mario Zappia (Italy)

18.00-18.30 Discussion

18.30-19.30 Behavioural and psychological symptoms of dementia: which strategies for the treatment?
   Peter De Deyn (Belgium)

19.30-19.40 Questionnaire
Friday July 16th, 2010

Use of antipsychotics in children and adolescents: assessing efficacy and safety

10.00-11.00  Efficacy and safety of antipsychotics in early onset psychosis  
Celso Arango (Spain)

11.00-12.00  Antipsychotics for non-psychotic disorders  
Alessandro Zuddas (Italy)

12.00-12.30  Discussion

12.30-12.45  Closing remarks  
Filippo Drago (Italy)

12.45-12.55  Questionnaire